Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1995 1
1996 1
1998 1
1999 1
2002 1
2003 3
2004 3
2005 2
2006 2
2007 6
2008 3
2009 6
2010 7
2011 7
2012 13
2013 19
2014 18
2015 20
2016 29
2017 18
2018 20
2019 34
2020 20
2021 20
2022 24
2023 25
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for francesca random
Search for Francesca Randon instead (1 results)
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.
Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, Darby SC, Taylor CW. Kerr AJ, et al. Cancer Treat Rev. 2022 Apr;105:102375. doi: 10.1016/j.ctrv.2022.102375. Epub 2022 Mar 4. Cancer Treat Rev. 2022. PMID: 35367784 Free PMC article. Review.
Radiotherapy options were after breast conserving surgery (whole breast, partial breast, tumour bed boost, regional nodes) and after mastectomy (chest wall, regional nodes). Treatment options were supported by randomised evidence, including > 10,000 women for eight trea …
Radiotherapy options were after breast conserving surgery (whole breast, partial breast, tumour bed boost, regional nodes) and after mastect …
Non-Pharmacological Approaches for Migraine.
Puledda F, Shields K. Puledda F, et al. Neurotherapeutics. 2018 Apr;15(2):336-345. doi: 10.1007/s13311-018-0623-6. Neurotherapeutics. 2018. PMID: 29616493 Free PMC article. Review.
GLP-1 Receptor Agonists and Kidney Protection.
Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. Greco EV, et al. Medicina (Kaunas). 2019 May 31;55(6):233. doi: 10.3390/medicina55060233. Medicina (Kaunas). 2019. PMID: 31159279 Free PMC article. Review.
Clinical benefits of GLP-1R agonists were acknowledged due to data from large randomized phase III clinical trials conducted to assess their cardiovascular(CV) safety. ...
Clinical benefits of GLP-1R agonists were acknowledged due to data from large randomized phase III clinical trials conducted to asses …
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M. McCarthy PL, et al. J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25. J Clin Oncol. 2017. PMID: 28742454 Free PMC article.
Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma …
Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival …
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
The median duration of follow-up was 37.3 months (IQR 32.9-41.9) from the second randomisation. 3-year progression-free survival was 75% (95% CI 68-82) with carfilzomib plus lenalidomide versus 65% (58-72) with lenalidomide alone (hazard ratio [HR] 0.64 [95% CI 0.44-0.94], …
The median duration of follow-up was 37.3 months (IQR 32.9-41.9) from the second randomisation. 3-year progression-free survival was …
The treatment of obesity in children and adolescents: consensus position statement of the Italian society of pediatric endocrinology and diabetology, Italian Society of Pediatrics and Italian Society of Pediatric Surgery.
Maffeis C, Olivieri F, Valerio G, Verduci E, Licenziati MR, Calcaterra V, Pelizzo G, Salerno M, Staiano A, Bernasconi S, Buganza R, Crinò A, Corciulo N, Corica D, Destro F, Di Bonito P, Di Pietro M, Di Sessa A, deSanctis L, Faienza MF, Filannino G, Fintini D, Fornari E, Franceschi R, Franco F, Franzese A, Giusti LF, Grugni G, Iafusco D, Iughetti L, Lera R, Limauro R, Maguolo A, Mancioppi V, Manco M, Del Giudice EM, Morandi A, Moro B, Mozzillo E, Rabbone I, Peverelli P, Predieri B, Purromuto S, Stagi S, Street ME, Tanas R, Tornese G, Umano GR, Wasniewska M. Maffeis C, et al. Ital J Pediatr. 2023 Jun 8;49(1):69. doi: 10.1186/s13052-023-01458-z. Ital J Pediatr. 2023. PMID: 37291604 Free PMC article. Review.
In particular, new drugs demonstrated their efficacy and safety and have been approved in adolescents. Moreover, several randomized control trials with other drugs are in process and it is likely that some of them will become available in the future. ...
In particular, new drugs demonstrated their efficacy and safety and have been approved in adolescents. Moreover, several randomized c …
Treating early-stage myelofibrosis.
Palandri F, Sabattini E, Maffioli M. Palandri F, et al. Ann Hematol. 2019 Feb;98(2):241-253. doi: 10.1007/s00277-018-3526-z. Epub 2018 Oct 20. Ann Hematol. 2019. PMID: 30343328 Review.
Overall, therapies used to treat patients with early-stage MF will have to be assessed in randomized studies, with the potential benefits balanced against adverse events associated with treatment....
Overall, therapies used to treat patients with early-stage MF will have to be assessed in randomized studies, with the potential bene …
Endometriosis and irritable bowel syndrome: a systematic review and meta-analysis.
Chiaffarino F, Cipriani S, Ricci E, Mauri PA, Esposito G, Barretta M, Vercellini P, Parazzini F. Chiaffarino F, et al. Arch Gynecol Obstet. 2021 Jan;303(1):17-25. doi: 10.1007/s00404-020-05797-8. Epub 2020 Sep 19. Arch Gynecol Obstet. 2021. PMID: 32949284 Free article.
All three studies considering the incidence of IBS in women with a previous diagnosis of endometriosis showed about twofold greater risk among women with endometriosis than women without. Likewise, in the random effects model of the meta-analysis, the overall OR of history …
All three studies considering the incidence of IBS in women with a previous diagnosis of endometriosis showed about twofold greater risk amo …
273 results